Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Samsung
Elon Musk
Apple
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Technology News / UK scientists trial instant immunity antibody drug treatment for COVID-19
Technology

UK scientists trial instant immunity antibody drug treatment for COVID-19

UK scientists trial instant immunity antibody drug treatment for COVID-19
Written by Srijita Sen
(Sourced from PTI)
Dec 27, 2020, 12:31 pm 3 min read
UK scientists trial instant immunity antibody drug treatment for COVID-19

Scientists in the UK have begun trials of innovative instant immunity antibody-drug treatments for COVID-19. The University College London Hospitals NHS Trust (UCLH) said researchers in the Storm Chaser study believe a Long-Acting AntiBody (LAAB) known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to the SARS-CoV-2 coronavirus and prevent them from developing COVID-19.

Details
'This antibody combination can neutralize the virus'

The world's first participant to the UCLH virologist Dr. Catherine Houlihan-led study was recruited earlier this month; nine more were recruited later. Houlihan said as the antibody combination can neutralize the virus, they hope to find that injecting this can lead to immediate protection against the development of COVID-19 in people who've been exposed and when it is too late to offer a vaccine.

Details
UCLH's new vaccine research center is running two clinical trials

UCLH said its new vaccine research center is running two clinical trials testing a LAAB combination treatment to protect against COVID-19. The second Provent study is looking at the use of AZD7442 in people who may not respond to vaccination, for instance where someone has a compromised immune system or are at increased risk of COVID-19 infection due to old age and existing conditions.

Statement
Older people and people with pre-existing conditions to be recruited

"We want to reassure anyone for whom a vaccine may not work that we can offer an alternative which is just as protective," said Dr. Nicky Longley, UCLH infectious diseases consultant leading the Provent study. She also said will recruit people who are older or in long-term care, and those with pre-existing conditions like cancer and HIV that can weaken their immune system.

Quote
'Antibody treatment may offer an alternative'

"These two clinical trials are an important addition to testing new therapeutic approaches, as antibody treatments may offer an alternative to patient groups who cannot benefit from a vaccine, such as immunocompromised patients," said Professor Stephen Powis, the medical director of National Health Service, England.

Information
What makes Storm Chaser an important study?

Storm Chaser is exploring the use of a combination of monoclonal antibodies given intramuscularly to those who have been exposed to SARS-CoV-2—a setting where vaccination would not have time to work. This makes Storm Chaser an important study that may have a large impact on our ability to control this infection, noted Professor Andrew Ustianowski, who is the chief investigator of the new studies.

Information
Technology to increase the durability of the therapy

The LAABs have been engineered with AstraZeneca's "proprietary" half-life extension technology to increase the durability of the therapy for six to 12 months following a single administration. The combination of two LAABs is designed to reduce the risk of resistance developed by the SARS-CoV-2 virus.

Information
The Storm Chaser trial to include healthcare workers, students

UCLH said that in both the studies, researchers will assess whether the treatment reduces the risk of developing COVID-19 and/or reduces the severity of infection compared to placebo. The Storm Chaser trial will include healthcare workers, students living in group accommodation, and patients who are exposed to anyone with the virus as well as residents of long-term care facilities and industrial/military settings.

Details
The importance of these additional treatments

"The opening of our new Vaccine Research Center will help to propel our fight against the virus, meet our aspiration to save as many lives as possible, and ensure a return to normality," said Professor Vincenzo Libri, Director, UCLH Clinical Research Facility. Professor Marcel Levi, UCLH Chief Executive, said developing additional treatments will be vital to ensure everyone can be offered protection against COVID-19.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Srijita Sen <br/><i>(Sourced from PTI)</i>
Srijita Sen
(Sourced from PTI)
Mail
Latest
Coronavirus
Related
Latest
Gyanvapi row: Delhi University professor arrested over 'derogatory' Shivling post
Gyanvapi row: Delhi University professor arrested over 'derogatory' Shivling post India
Hero Splendor Plus XTEC debuts in India at Rs. 73,000
Hero Splendor Plus XTEC debuts in India at Rs. 73,000 Auto
MEA confirms 'illegal' Chinese construction of two bridges in Pangong
MEA confirms 'illegal' Chinese construction of two bridges in Pangong India
'Dhaakad' review: Kangana Ranaut is captivating in hardcore action extravaganza
'Dhaakad' review: Kangana Ranaut is captivating in hardcore action extravaganza Entertainment
International Tea Day: Exploring India's position in the global market
International Tea Day: Exploring India's position in the global market Lifestyle
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Related
Kerala has least COVID-19 antibodies: ICMR's national serosurvey
Kerala has least COVID-19 antibodies: ICMR's national serosurvey India
Next News Article
Next News Article

Love Technology news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022